ArticlePloS one2017

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

Juliana Maynard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.